PROTAC technology for prostate cancer treatment
Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men. PrCa is marked by uncontrolled cellular growth that leads to abnormal enlargement of the prostate gland. The metastatic spread of PrCa is the primary cause of mortality, causing cancer cell dissemination to distant sites,...
Saved in:
Main Authors: | Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, Wenyi Wei |
---|---|
Format: | Article |
Language: | English |
Published: |
Compuscript Ltd
2025-01-01
|
Series: | Acta Materia Medica |
Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0075 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PROTAC-based therapeutics for targeting HPV oncoproteins in head and neck cancers
by: Nobendu Mukerjee, et al.
Published: (2025-12-01) -
Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
by: Guliang Yang, et al.
Published: (2022-03-01) -
PROTACs: Mechanism and Bioavailability enhancement strategies by nanotechnology, RNA viral infections (vaccine strategy) and Prodrug development
by: Sanaul Mustafa, et al.
Published: (2025-01-01) -
A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines
by: Linghong Huang, et al.
Published: (2025-04-01) -
Fortifying the Treatment of Prostate Cancer with Physical Activity
by: Colin E. Champ, et al.
Published: (2016-01-01)